Most medical device companies begin with an engineer’s concept and then search for a clinical problem to solve. RC Medical, a venture studio based in Lake Forest, California, takes the opposite approach. “We go to the interventional suite first,” said David Ferrera, CEO of RC Medical. “The physicians there see the gaps every week. Our job is to listen, then build the company around what they’re actually describing.”
RC Medical funds, designs, develops, and commercializes products for the interventional radiology market. Rather than performing contract work for outside clients, the studio partners directly with physician-entrepreneurs to identify new technology and new indications for devices, then forms a standalone company to carry each idea forward. That structure matters because it keeps clinical needs at the center of product development from the earliest stages, when designs are still flexible and inexpensive to change.
The studio model differs sharply from traditional corporate development. When a physician brings an idea to RC Medical, the relationship is a partnership that runs from the first sketch through commercialization. “A physician knows the problem better than anyone,” Ferrera said. “What we bring is the engineering, the regulatory path, and the discipline to turn that problem into something that can actually reach patients. Neither side can do it alone.” The physician remains close to the clinical need while RC Medical manages product development, funding, and the business structure required to commercialize it.
When an idea clears the studio’s early evaluation, RC Medical does not fold it into an existing product line. Instead, it forms a new company around it. “Each idea gets its own company, its own team, its own focus,” Ferrera said. “A big portfolio company can lose a good idea in the shuffle. A newco can’t afford to.” That approach has produced three separate companies: Single Pass, Infinity Neuro, and Sonorous NV. Each grew out of a specific problem a physician described in the interventional suite and operates as its own business rather than a product line inside RC Medical.
Ferrera’s perspective is informed by close to three decades in medical devices for interventional neuroradiology and related fields, including co-founding Blockade Medical, which was acquired by Balt Extrusion in 2016, and serving as chief technology officer of Balt Global. He argues that physicians in these procedures see problems that never make it into a traditional product roadmap. “A catheter that works in a textbook case can still fail in the specific anatomy a physician sees three times a week,” he said. “That detail doesn’t show up unless you’re building with the physician, not for them.” The studio model is designed to catch such details early, before a device design is locked in and difficult to change.
Not every idea fits the model. Ferrera said some concepts are better suited as a feature of an existing product rather than the basis for a new company, and part of the first conversation with a physician is being honest about which path applies. For ideas that do become new companies, the physician’s involvement often continues through development and toward the market, keeping the clinical need in view at every stage. The implication for interventional radiology is a development pipeline that starts with the people who perform the procedures, potentially bringing devices to patients faster and with better alignment to real-world clinical demands.
